Media stories about Humana (NYSE:HUM) have trended somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Humana earned a news impact score of 0.10 on Accern’s scale. Accern also assigned press coverage about the insurance provider an impact score of 45.5550157387877 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

These are some of the media headlines that may have impacted Accern Sentiment’s rankings:

Humana (NYSE:HUM) traded up $5.58 on Wednesday, reaching $275.75. The company had a trading volume of 1,116,839 shares, compared to its average volume of 1,203,518. The company has a current ratio of 1.61, a quick ratio of 1.61 and a debt-to-equity ratio of 0.35. Humana has a fifty-two week low of $186.25 and a fifty-two week high of $276.07. The company has a market cap of $39,320.00, a price-to-earnings ratio of 21.71, a price-to-earnings-growth ratio of 1.68 and a beta of 0.88.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, November 8th. The insurance provider reported $3.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.27 by $0.12. Humana had a return on equity of 15.99% and a net margin of 3.49%. The business had revenue of $13.28 billion for the quarter, compared to analyst estimates of $13.41 billion. During the same period last year, the company earned $3.18 EPS. Humana’s revenue for the quarter was down 3.0% compared to the same quarter last year. equities research analysts anticipate that Humana will post 11.63 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, January 26th. Investors of record on Friday, December 29th will be given a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, December 28th. This represents a $1.60 annualized dividend and a yield of 0.58%. Humana’s payout ratio is 12.60%.

Humana announced that its Board of Directors has authorized a share buyback program on Thursday, December 14th that allows the company to repurchase $3.00 billion in outstanding shares. This repurchase authorization allows the insurance provider to repurchase shares of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s board believes its shares are undervalued.

Several research firms have weighed in on HUM. Jefferies Group raised Humana from a “hold” rating to a “buy” rating and set a $221.00 price target on the stock in a report on Friday, January 12th. Zacks Investment Research raised Humana from a “hold” rating to a “buy” rating and set a $297.00 price objective on the stock in a report on Monday. JPMorgan Chase & Co. cut Humana from an “overweight” rating to a “neutral” rating and set a $253.00 price objective on the stock. in a report on Monday, October 9th. Goldman Sachs Group initiated coverage on Humana in a report on Wednesday, January 3rd. They set a “buy” rating and a $305.00 price objective on the stock. Finally, ValuEngine cut Humana from a “buy” rating to a “hold” rating in a report on Tuesday, October 10th. Nine investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. Humana has an average rating of “Buy” and a consensus price target of $260.10.

In other news, VP Timothy S. Huval sold 1,382 shares of Humana stock in a transaction that occurred on Tuesday, December 19th. The stock was sold at an average price of $246.04, for a total value of $340,027.28. Following the sale, the vice president now directly owns 11,557 shares in the company, valued at approximately $2,843,484.28. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Jody L. Bilney sold 7,054 shares of Humana stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $247.89, for a total value of $1,748,616.06. Following the completion of the sale, the senior vice president now owns 11,704 shares in the company, valued at $2,901,304.56. The disclosure for this sale can be found here. Over the last quarter, insiders sold 10,115 shares of company stock worth $2,501,627. Corporate insiders own 0.80% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international copyright & trademark law. The original version of this piece of content can be read at

About Humana

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Insider Buying and Selling by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with's FREE daily email newsletter.